ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tucidinostat

Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.

Drug pageTucidinostat: every studyAll 185 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 17, 201519 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciences92 open or runningphase 3since Jun 17, 2015Apr 12, 2013May 31, 2028phase 3 · NCT06497985
HUYABIO International, LLC.its history only71 open or runningphase 3since Dec 7, 2020Oct 5, 2015none ahead
Great Novel Therapeutics Biotech & Medicalsits history only21 open or runningphase 2since Feb 7, 2023Feb 7, 2023Jun 2027phase 2 · NCT05833724
Jiangsu HengRui Medicineits history only11 open or runningphase 3since Nov 5, 2023Nov 5, 2023none ahead

Also a collaborator on its studies: Bristol-Myers Squibb and Iqvia Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 12, 2013First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT01836679 · 124 enrolled · China
  2. Jun 17, 2015Phase 3 study in Breast NeoplasmsNCT02482753 · 365 enrolled · China
  3. Jun 9, 2016Named tucidinostatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HBI-8000
  4. Jun 17, 2016Phase 1 study in Lymphoma, T-Cell, PeripheralNCT02809573 · 30 enrolled · China
  5. May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinNCT03974243 · 9 enrolled · China
  6. Jan 14, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04231448 · 423 enrolled · China
  7. Sep 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05068427 · 34 enrolled · China
  8. Aug 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05519865 · 118 enrolled · China
  9. Jun 28, 2024Phase 3 study in Colorectal NeoplasmsNCT06497985 · 430 planned · China
  10. Apr 25, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralNCT06947967 · 224 planned · China

Ahead

  1. May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT06497985
  2. Dec 2032Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralNCT06947967

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 Chipscreen Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06947967Lymphoma, T-Cell, Peripheral · China3RecruitingDec 2032224
NCT06497985Colorectal Neoplasms · China3RecruitingMay 31, 2028430
NCT05519865Carcinoma, Non-Small-Cell Lung · China2CompletedNov 18, 2024118
NCT05068427Carcinoma, Non-Small-Cell Lung · China2CompletedFeb 23, 202334
NCT04231448Lymphoma, Large B-Cell, Diffuse · China3CompletedJan 10, 2023423
NCT03974243Lymphoma, Non-Hodgkin · China2CompletedDec 31, 20219
NCT02809573Lymphoma, T-Cell, Peripheral · China1CompletedJan 8, 201930
NCT02482753Breast Neoplasms · China3CompletedMar 2018365
NCT01836679Carcinoma, Non-Small-Cell Lung · China2CompletedMay 2015124

How it is read

Names in the registry

  • “Chidamide”, 7 entries
  • “Tucidinostat”, 4 entries
  • “HBI-8000”, 4 entries
  • “HBI-8000 in combination with nivolumab”, 2 entries
  • “SHR2554 analog tablets; Chidamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.